ArgenxARGX stock toppled Monday after the biotech scrapped plans to develop its blockbuster drug, Vyvgart, for an autoimmune condition that attacks the eyes.The decision comes after an independent ...

Viridian Therapeutics’ phase 3 thyroid eye disease (TED) clinical trial has hit its primary and secondary endpoints. But with Amgen’s Tepezza already on the market, the data leave scope to question ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today ...

- Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED); veligrotug has the potential to transform the ...

The FDA granted priority review to veligrotug for the treatment of thyroid eye disease, according to a press release from ...

Viridian Therapeutics focuses on precision-driven biological research targeting rare and complex autoimmune conditions.

Thyroid eye disease (TED) therapy Tepezza – the biggest asset in Amgen's $26 billion takeover of Horizon last year – could soon face competition from a drug in the same class from Viridian ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...

Viridian Therapeutics (VRDN) announced that the FDA has accepted the biologics license application for veligrotug for the treatment of thyroid eye ...

Viridian is attempting to muscle in on Horizon Therapeutics' turf with a rival to Thyroid Eye Disease Therapy Tepezza. Tepezza is driving >$2bn in annual revenue for Horizon and Amgen is poised to ...

Viridian Weapon Technologies has announced the REACTOR R5 Gen 2 Green Laser Sight and the E-SERIES Red Laser Sight for the P365. Viridian Weapon Technologies has announced the availability of two new ...